ACCESS Newswire

mymediset

28.3.2024 12:12:56 CET | ACCESS Newswire | Press release

Share
mymediset LiveSync: mymediset and Terso Solutions Announce a New Partnership to Deliver a Revolutionary Supply Chain Platform for Live Consignment Tracking and Automation

FREIBURG, GERMANY / ACCESSWIRE / March 28, 2024 / mymediset, the leading provider of SAP solutions for the medical device industry, and Terso Solutions, the leading provider of RFID tracking solutions for the life sciences and healthcare markets, have today announced a new partnership to launch mymediset LiveSync, a revolutionary platform that will transform the way consigned inventory is identified, managed and tracked across mission-critical supply chains worldwide.

The new platform combines mymediset's cloud-based SAP automation solutions and Terso's RAIN RFID enclosures (cabinets, freezers, refrigerators) and sensors to provide real-time visibility and control of consigned products in the life sciences industries, such as medical devices, loaner kits, and pharmaceuticals. The platform, which will be launched in Q3/2024, is the first of its kind to combine live tracking and inventory data for medical and pharmaceutical consignments that is integrated into an intelligent, open, and extensible platform that provides complete visibility and control across the full product lifecycle from manufacture-to-disposal or recycling.

"This co-innovation initiative was brought together by mymediset and Terso Solutions in response to the multi-billion-dollar problem of inventory over-stocking caused by lack of real-time visibility and missing tracking data 'dead zones' that occur as consignments cycle through the different supply chain systems operated by manufacturers, distributors, and hospitals," said Michael Knauer, CEO & Founder of mymediset.

Joe Pleshek, CEO and President of Terso Solutions added: "Current industry estimates project, that several billion dollar of excess, unrecorded, or lost inventory may exist to assure product availability in mission-critical healthcare and lifesciences environments. With consignment records spanning numerous siloed systems and fragmented data sources, activities such as integrated planning, inventory rationalization and efficient automation of operations such as replenishment, disposal and recycling have so far been too costly and too complex for any one operator to resolve."

Knauer continued: "With our new mymediset LiveSync solution, we can now connect MedTech and Pharma manufacturers, distributors, and hospitals in a seamless, visible lifecycle, enabling customers to see, know, optimize, and automate every consignment wherever it is in the cycle. This provides an invaluable solution that can be used to rationalize inventory levels, reduce costs, improve patient safety, and comply with regulatory requirements and it provides the fundamental building block for our customers to create next-generation supply chains."

mymediset LiveSync Benefits:

  • Brings together the market leading capabilities of mymediset and Terso Solutions. Combining mymediset's platform, a software-as-a-service (SaaS) solution and Terso's RAIN RFID enabled enclosures and sensors, to automatically capture consignment movements in real time. Automates the entire consignment process, from order placement to invoicing, using smart algorithms and data analytics to manage complex consignment and field inventory processes inside SAP.
  • Connects all stakeholders involved in the consignment cycle and provides them with actionable insights and reports on inventory status, consumption, expiration, and replenishment.
  • Terso's RFID enclosures and sensors are connected to the cloud and transmit the inventory data to mymediset's platform in real-time, eliminating the need for manual scanning, counting, or reporting. The enclosures provide secure access control and track environmental data including temperature to ensure product integrity.
  • A seamless and scalable cloud-based SaaS solution for consignment automation that will benefit both suppliers and customers. The product will enable suppliers to increase sales, improve cash flow, and enhance customer satisfaction by ensuring the right products are available at the right time and place.
  • Enable customers to reduce inventory waste, avoid stock-outs, and improve patient outcomes by having access to the latest supplies, equipment, and devices, instantly locatable at the touch of a button.

Commenting on the partnership both CEOs pointed to the potential for customers to gain significant value from the new combination:

"We are very excited to partner with Terso Solutions and leverage their expertise and innovation in RFID technology. Together, we will offer a unique and powerful platform that will solve the challenges and inefficiencies of consignment management in the medical and life sciences industries. Our product will create value for our customers and help them achieve new levels of operational excellence and competitive advantage as they take on the challenge of running leaner, faster inventory lifecycles in next-generation supply chains driven by real-time data and assisted by AI. Two market leaders have come together to bring real-time transparency to the healthcare and life sciences industries. Finally, now we know what, where, and when products have been consumed, in real time" said Knauer.

"We are thrilled to partner with mymediset and integrate their SAP-based Enterprise SaaS platform with our RFID enabled solutions. Both mymediset and Terso have a proven track record of delivering consignment automation solutions that are trusted in the most demanding, mission-critical environments. Our product will provide a complete and end-to-end solution for consignment automation that will revolutionize the way consigned inventory is managed and tracked. With this innovative solution, We Know Now." said Pleshek.

The new product will be available for pre-order in April 2024 and will be launched in Q3 2024.

About mymediset

mymediset is the leading provider of cloud-based automation solutions for the medical device industry that specializes in managing complex loan, consignment, and field inventory processes inside SAP®. mymediset offers a platform that connects medical device and pharma manufacturers, distributors, hospitals, and clinics, and enables them to manage and track their consigned inventory in real-time. mymediset helps its customers reduce costs, increase sales, and optimize inventory levels, while ensuring compliance and patient safety.

About Terso Solutions, Inc.

Terso Solutions, Inc. is the leading provider of automated inventory management solutions for tracking high-value medical and scientific products in healthcare and life science. Terso is backed by 18 years of RFID product development and implementation experience, with a product line that includes RAIN RFID cabinets, refrigerators, freezers (-86°C to -5°C), read points, mobile solutions, and rooms. Terso has deployed over 3,500 RAIN RFID-enabled devices worldwide and provides inventory automation at over 1,000 U.S. healthcare facilities. Headquartered in Madison, WI, with additional offices in Walldorf, Germany and Tokyo, Japan, Terso Solutions, Inc. is a wholly owned subsidiary of the Promega Corporation.

For press inquiries, please contact:

mymediset:
Gloriela Rosas
LiveSync@mymediset.cloud
Phone:
North America: +1 (617) 506 9850
Europe: +49 (761) 556-5580
Terso Solutions:
Katie Anderson
katie.anderson@tersosolutions.com
Phone:+1 (608) 960-7376
For more information, please visit:
mymediset:https://mymediset.net/
https://mymediset.net/livesync/
Terso Solutions:www.tersosolutions.com

SOURCE: mymediset



View the original press release on accesswire.com

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Datavault AI Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2025 Accomplishments and Outlook for 20265.2.2026 12:00:00 CET | Press release

Datavault AI signed $49M of Tokenization and Technology Licensing agreements in Q4'25 that impact FY2025 and FY2026 Revenue. Revenue: Datavault AI expects at least $30 million in revenue for FY2025, compared to $2.7 million in FY2024. This represents an increase of more than 1,000% growth in our revenue over 2024. The Company continues to expand to drive substantial near- and long-term accretion to our cash flows and earnings with a revenue target for 2026 of at least $200 million. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / February 5, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, digital engagement and real-world asset (RWA) tokenization technologies, today issued a letter from Nathaniel Bradley, its Chief Executive Officer, to its stockholders highlighting the Company's accomplishments in 2025 and its outlook for 2026. A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER Dear Datavault AI Stockholders, I would like t

AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States4.2.2026 15:45:00 CET | Press release

Industry recognition for the third consecutive year reinforces AGFA HealthCare's clinician-first commitment, and leadership in empowering connected, high-performance imaging environments MORTSEL, BE / ACCESS Newswire / February 4, 2026 / AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide. The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights. AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinica

Preservica Redefines Digital Preservation with Powerful Built-In AI Tools4.2.2026 15:00:00 CET | Press release

OXFORD, UK and BOSTON, MA / ACCESS Newswire / February 4, 2026 / Preservica, the leader in AI-powered Active Digital Preservation™, today announced the rollout of integrated, human-centered AI tools and flexible AI Credits across its product editions. These new features make AI assistance a seamless part of everyday archival workflows, empowering organizations of all sizes to safely adopt AI and scale its use as their needs grow. "With the sheer volume of digital content in backlogs and being created daily, using AI to assist in archival tasks has now become essential" says Stuart Reed, Chief Product Officer at Preservica "Seamlessly integrating human-centered AI tools across our product editions turns AI for Digital Preservation into reality - enabling organizations of all sizes to accelerate routine work, cut backlogs and enhance discovery." Developed in collaboration with Preservica's user community and refined through the company's highly rated AI Workshop series, these embedded to

Karbon-X Files Quarterly Report on Form 10-Q Highlighting Strong Revenue Growth and Commercial Scale4.2.2026 15:00:00 CET | Press release

CALGARY, AB / ACCESS Newswire / February 4, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the six months ended November 30, 2025. The filing highlights continued momentum in Karbon-X's commercial operations, driven by significant revenue growth and the expansion of its global carbon activities across both compliance and voluntary markets. "Over the past several quarters, we transformed Karbon-X from a developing platform into a scaled, revenue-generating global operator," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "Revenue increased to $56.5 million (USD), compared to $1.3 million (USD) in the prior-year period, reflecting the strength of our commercial strategy and the growing demand for high-integrity carbon solutions. As we continue to invest in scaling our operations, our expanding global footprint, improved profitability, a

Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant4.2.2026 14:00:00 CET | Press release

Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer's disease phase 2 clinical trial (supported by a USD 151 million grant) and, simultaneously, a new platform trial for progressive supranuclear palsy (PSP) (supported by a USD 75 million grant) SAN FRANCISCO, CA / ACCESS Newswire / February 4, 2026 / Axon Neuroscience, a global leader in immunotherapy for human neurodegenerative diseases with an internationally recognized scientific team, announces the achievement of two historic milestones with the potential to significantly influence the future treatment of Alzheimer's disease and progressive supranuclear palsy (PSP): 1. AADvac1 Selected as the First Tau Therapy in the Phase 2 Alzheimer's Tau Platform (ATP) Combination-Therapy Trial An independent panel of leading U.S. scientific and clinical experts selected AADvac1 as the first therapy targeting pathological tau protein to be evaluated in

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye